Glucose News and Research

RSS

Scientist suggests emodin can reduce impact of type 2 diabetes

Emodin, a natural product that can be extracted from various Chinese herbs including Rheum palmatum and Polygonum cuspidatum, shows promise as an agent that could reduce the impact of type 2 diabetes. Findings published in this month's edition of the British Journal of Pharmacology show that giving emodin to mice with diet-induced obesity lowered blood glucose and serum insulin, improved insulin resistance and lead to more healthy levels of lipid in the blood. It also decreased body weight and reduced central fat mass.

18 Aug 2010

Bariatric surgery can result in sustained reversal of obesity, type 2 diabetes: Study

Results of a large national study show that nearly three-quarters of obese patients with type 2 diabetes who undergo weight-loss surgery are able to stop insulin and other antidiabetes drugs within six months. In the Johns Hopkins study of insured, obese, diabetic patients, researchers also found that in the third year following surgery, average annual health care costs per patient decreased by more than 70 percent. The study is published in the Archives of Surgery this month.

17 Aug 2010

JDRF announces key step on road to artificial pancreas

JDRF announced today another important step on the road to the development of an artificial pancreas - an automated system to better manage the blood sugar of people with type 1 diabetes - with the establishment of a research program to speed the development of faster-acting insulin.

17 Aug 2010

Thickening of neck artery wall increases risk of heart attack, stroke: Study

Researchers for the U.S. National Institute on Aging (NIA), a component of the National Institutes of Health (NIH), studied 5,614 Italians in four villages and found that those who scored high for antagonistic traits on a standard personality test had greater thickening of the neck (carotid) arteries compared to people who were more agreeable. Thickness of neck artery walls is a risk factor for heart attack and stroke.

17 Aug 2010

Smart for Life continues to improve Chocolate Chip Cookie

The trailblazing company whose Smart for Life weight management products featuring the cookie diet component has recently improved its Chocolate Chip Cookie to include the most protein offered in a meal replacement cookie on the market at a whopping 6 grams per serving. The amount of protein found in meal replacements is instrumental in curbing hunger, maintaining muscle mass, and providing energy, not to mention contributing to weight loss.

16 Aug 2010

Low socioeconomic status, stressful childhood events develop risk of cardiovascular disease

Early life adversity through poverty, social isolation or abuse in childhood is linked to heightened reactivity, which can lead to heart disease later on, a leading expert on stress and disease said Saturday."Many diseases first diagnosed in mid-life can be traced back to childhood," Karen A. Matthews, PhD, said at the 118th Annual Convention of the American Psychological Association. "Having some bad health habits in your 20s and 30s is part of the reason why people get diseases later on. However, it isn't the whole reason. The evidence shows that certain reactions to adverse childhood experiences associated with lower socioeconomic status, isolation and negative events can affect the disease process."

16 Aug 2010

Study examines impact of microvascular decompression surgery for type 2 diabetes

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progression of type 2 diabetes mellitus.Reporting today in the journal Surgical Neurology International, Dr. Jannetta and his colleagues present evidence from a prospective clinical trial that vascular compression of a section of the brain called the medulla oblongata is a factor in some patients with type 2 diabetes and that microvascular decompression surgery (MVD) may be an effective treatment for the condition.

13 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

Researchers have been able to use a common chaperone protein, Hsp70, to reverse the loss of function in the nerves of mice with diabetes.Writing in ASN NEURO, Michael J. Urban and colleagues at the University of Kansas suggest that Hsp70 could be used in the future to cure the loss of feeling in the limbs that afflicts many diabetics.

12 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

Increased brain activity predicts anxious temperament in young primates

A new study focused on anxiety and brain activity pinpoints the brain regions that are relevant to developing childhood anxiety. The findings, published in the Aug. 12 edition of the journal Nature, may lead to new strategies for early detection and treatment of at-risk children.

12 Aug 2010

Survey finds prevalence of diabetic retinopathy high among U.S. adults

Nearly 30 percent of U.S. adults with diabetes over the age of 40 are estimated to have diabetic retinopathy, with about 4 percent of this population having vision-threatening retinopathy, according to a study in the August 11 issue of JAMA.

11 Aug 2010

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive agreement to leverage the translational research expertise of Dr. Jason Chesney, Associate Professor, Department of Medicine at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center), to identify new clinical candidates for the prevention and treatment of cancers against two key cancer metabolic targets.

11 Aug 2010

Weifang Shengtai to supply Kelun with 10,000 tons of dextrose monohydrate injection grade

Shengtai Pharmaceutical, Inc. announced on August 6, 2010 that Weifang Shengtai Pharmaceutical Co., Ltd ("Weifang Shengtai"), its operating subsidiary in China, entered into an agreement with Kelun Pharmaceutical ("Kelun") to supply Kelun with 10 thousand tons of dextrose monohydrate injection grade: Kelun Guizhou will be supplied with 7 hundred tons and Kelun Sichuan with 9.3 thousand tons. The agreement is entered into at reasonable prices and will be carried out by prepayments.

10 Aug 2010

Oil rig workers access healthcare via telemedicine

Without hands-on access to doctors and hospitals, oil rig workers who become sick or injured increasingly rely on telemedicine "visits" with physicians and specialists on land, a trend explored in detail in an article published in Telemedicine and e-Health, a peer-reviewed journal published by Mary Ann Liebert, Inc.

10 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.

9 Aug 2010

Researchers examine differences in eating habits of African Americans

Researchers looking for differences in eating habits of African Americans based on whether or not they had Type 2 diabetes uncovered an unexpected result: No matter what the blood sugar level was, the dietary intakes were pretty much the same.

7 Aug 2010

Orexigen second-quarter net loss decreases to $11.9 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2010. For the quarter ended June 30, 2010, Orexigen reported a net loss of $11.9 million, or $0.25 per share attributable to common stockholders, as compared to a net loss of $17.8 million, or $0.51 per share attributable to common stockholders, for the second quarter of 2009.

7 Aug 2010

Ongoing diabetes education continues to deliver better health results: Study

Preliminary data from a study of private insurance and Medicare claims commissioned by the American Association of Diabetes Educators reveal that ongoing diabetes education continues to deliver results in terms of better health and reduced private insurance and Medicare claims.

7 Aug 2010